Core Insights - BD has achieved full enrollment of the iliac artery patient cohort in its AGILITY study, which evaluates the Revello™ Vascular Covered Stent for treating peripheral arterial disease (PAD) [1][4] - The AGILITY study is a multi-center, prospective study being conducted across 45 investigational sites in the U.S., Europe, Australia, and New Zealand [4] - PAD affects over 21 million Americans and more than 200 million people globally, highlighting the critical need for innovative treatment options [5] Company Overview - BD is a leading global medical technology company focused on improving medical discovery, diagnostics, and care delivery [6] - The company employs over 70,000 individuals and collaborates with organizations worldwide to tackle significant global health challenges [6] Study Details - The AGILITY study aims to assess the safety and effectiveness of the Revello™ Vascular Covered Stent for de novo or restenotic lesions in two patient cohorts: the common and external iliac artery cohort (n=118) and the superficial femoral and proximal popliteal artery cohort (n=223) [7] - The study represents a significant advancement in self-expanding covered stent technology, addressing the need for improved flexibility and deliverability in PAD treatment [3][4]

Core Insights - BD (Becton, Dickinson and Company) has received FDA 510(k) clearance and CE marking for its Enteric Bacterial Panel (EBP) and Enteric Bacterial Panel plus (EBP plus) for the BD COR™ System, enhancing diagnostic capabilities for gastrointestinal infections [1][2]. Group 1: Product Features and Benefits - The EBP and EBP plus utilize advanced Polymerase Chain Reaction (PCR) technology to test a wide range of gastrointestinal bacterial pathogens from a single stool swab, streamlining workflows for clinicians [1][2]. - The EBP plus is the only high-throughput, bacterial-only molecular panel that detects Enterotoxigenic Escherichia coli (ETEC) and associated toxins, improving patient management and reducing unnecessary antibiotic use [3]. - The BD COR™ System can automate nearly 1,650 tests and deliver up to 1,000 sample results in 24 hours, maximizing efficiency with minimal manual interaction [4]. Group 2: Market Context and Impact - Gastrointestinal infections lead to over 1.7 million deaths globally each year, with significant healthcare burdens in the U.S., including 179 million outpatient visits and 500,000 hospitalizations annually due to diarrhea [1]. - The introduction of these panels addresses the urgent need for rapid and accurate diagnostics, which is critical for improving patient outcomes and supporting antimicrobial stewardship [1][2]. Group 3: Company Overview - BD is one of the largest global medical technology companies, focused on advancing health through innovative technology and solutions that enhance clinical therapy and healthcare delivery [7][8]. - The company has a strong commitment to improving the safety and efficiency of healthcare processes, with a presence in virtually every country and partnerships aimed at addressing global health challenges [8].

Core Insights - Dividend Aristocrats are considered some of the best stocks to purchase during market downturns due to their strong financial foundations [1] Group 1 - Dividend Aristocrats are backed by companies with solid footing, making them reliable investment options [1]

Company Overview - Becton, Dickinson and Company (BDX) is valued at $52.3 billion and is a leading medical technology company based in Franklin Lakes, New Jersey, founded in 1897. The company develops, manufactures, and sells a variety of medical devices, laboratory equipment, and diagnostic products aimed at improving healthcare safety, efficiency, and quality worldwide [1]. Earnings Expectations - BDX is expected to announce its fiscal fourth-quarter earnings for 2025 on November 6, with analysts predicting a profit of $3.91 per share on a diluted basis, which represents a 2.6% decrease from $3.81 per share in the same quarter last year. The company has a track record of exceeding Wall Street's EPS estimates in the last four quarters [2]. - For the full fiscal year, analysts anticipate BDX will report an EPS of $14.40, reflecting a 9.6% increase from $13.14 in fiscal 2024. EPS is projected to rise by 2.7% year over year to $14.79 in fiscal 2026 [3]. Stock Performance - Over the past year, BDX stock has declined by 21.5%, underperforming the S&P 500 Index, which gained 14.5%, and the Health Care Select Sector SPDR Fund, which saw a 3.4% dip [4]. - On October 17, BDX shares increased by 2.1%, outperforming several competitors in the medical technology sector, following Piper Sandler analyst Jason Bednar's reaffirmation of a "Hold" rating with a $200 price target [5]. Analyst Ratings - The consensus opinion among analysts on BDX stock is moderately bullish, with an overall "Moderate Buy" rating. Out of 17 analysts, six recommend a "Strong Buy," one suggests a "Moderate Buy," and ten give a "Hold." The average analyst price target for BDX is $216.23, indicating a potential upside of 14.9% from current levels [6].

Core Insights - Fiduciary Management Inc. (FMI) reported a strong performance in the third quarter of 2025, with major stock indices such as the Russell 2000 and S&P 500 gaining 12.39% and 8.12% respectively, driven by a Federal Reserve rate cut and enthusiasm for AI and technology stocks [1] - FMI's investment strategy focuses on idiosyncratic dislocations, prioritizing business quality, balance sheet strength, and valuation while maintaining downside protection [1] Company Overview: Becton, Dickinson and Company (NYSE:BDX) - Becton, Dickinson and Company is a leading healthcare company specializing in medical supplies and devices, with a market capitalization of $54.201 billion and a share price of $189.03 as of October 21, 2025 [2] - The company experienced a one-month return of 1.70% but faced a significant decline of 21.33% over the past 52 weeks [2] Investment Thesis on Becton, Dickinson and Company - FMI views Becton, Dickinson and Company as a quality business with a strong competitive position in an oligopoly market, focusing on low-cost medical essentials [3] - The management's strategy aims for over 5% annual organic revenue growth and margin expansion, with a significant portion of revenue being recurring post-separation of its biosciences and diagnostics solutions business in 2026 [3] - The company's manufacturing scale and durable business model driven by healthcare utilization provide a competitive advantage, making its current valuation attractive given its defensive attributes and growth potential [3]

Core Insights - BD (Becton, Dickinson and Company) has announced a new self-collection solution for HPV testing aimed at enhancing cervical cancer screening accessibility globally [1][5]. Product Features - The new swab technology is certified under the In Vitro Diagnostic Medical Device Regulation (IVDR) in Europe, ensuring safety and simplicity for patients [2]. - The self-collection process is non-invasive, requiring no liquids or complex devices, and allows for easy mailing of samples from home to the lab [2][6]. - The BD COR™ System automates lab processing, eliminating manual sample preparation and enhancing laboratory efficiency [3][4]. Market Impact - The BD Onclarity™ HPV Self-Collection solution is expected to be commercially available in IVDR-recognized markets soon, supporting public health initiatives for cervical cancer screening [5]. - The innovation aims to improve participation in screening programs, particularly for underserved populations [4][5]. Company Overview - BD is a leading global medical technology company with over 70,000 employees, dedicated to advancing health care through innovative technologies and solutions [5].

Core Insights - Becton, Dickinson and Company (BDX) has launched the AI-enabled BD Incada Connected Care Platform and the next-generation BD Pyxis Pro Automated Medication Dispensing Solution, marking a significant advancement in its Connected Care strategy [1][7] - The BD Incada Platform, built on Amazon Web Services (AWS), integrates data from millions of smart devices to enhance medication availability and streamline workflows, reinforcing BD's leadership in digital healthcare innovation [2][4] Company Developments - The BD Incada Platform aims to transform device data into actionable intelligence, improving efficiency and patient safety through real-time analytics and natural language insights [8] - The BD Pyxis Pro Solution modernizes medication dispensing with enhanced storage, automation, and security features, addressing space constraints in hospitals while minimizing medication retrieval errors [9] Market Performance - Following the announcement of the new products, BDX shares remained flat, with a year-to-date decline of 15.8%, contrasting with the industry’s growth of 2.8% and the S&P 500's gain of 14.4% [3] - BDX currently holds a market capitalization of $52.2 billion [6] Strategic Positioning - The integration of AI, cloud connectivity, and real-time analytics positions BDX for long-term growth in the expanding digital healthcare ecosystem, driving recurring software and service revenues [4][10] - The convergence of hardware and AI analytics enhances BD's competitive advantage, opening opportunities in cloud services and subscription-based models, which could lead to steady margin expansion and long-term shareholder value creation [10]

Core Insights - The author, Albert Anthony, is a Croatian-American business author and media contributor with a focus on real estate investment trusts (REITs) [1] - He has a background in IT analysis for Fortune 500 companies and experience in financial services with Charles Schwab [1] - Albert Anthony is launching a book on REITs in 2025 and operates his own equities research firm remotely [1] Background and Experience - Albert Anthony has over 1,000 followers on Seeking Alpha and contributes to platforms like Investing.com [1] - He has participated in numerous business and innovation conferences in the EU and has a degree from Drew University [1] - Currently enrolled in the CMSA certification program at the Corporate Finance Institute in Vancouver [1] Media and Digital Presence - The author is active in digital media, including a YouTube channel focused on REITs [1] - He has appeared in regional media channels in Croatia and has had roles in over five productions [1] - Albert Anthony does not write about non-publicly traded companies or small-cap stocks [1]

Core Insights - BD (Becton, Dickinson and Company) has launched the BD Incada™ Connected Care Platform, an AI-enabled, cloud-based platform designed to unify device data into a single ecosystem, enhancing connectivity and actionable insights across healthcare settings [1][2]. Product Launch and Features - The BD Incada™ Platform is now available alongside the next-generation BD Pyxis™ Pro Automated Medication Dispensing Solution, which aims to create enterprise-wide visibility and connectivity [1][2]. - The BD Pyxis™ Pro Dispensing Solution features a flexible, stackable device configuration that increases medication storage capacity and improves access to medications at the point of care [3][6]. Technology and Analytics - Built on Amazon Web Services (AWS), the BD Incada™ Platform utilizes advanced AI technologies, including natural language search, to facilitate smarter and faster decision-making [2][5]. - The platform allows for enterprise-wide visibility into medication inventory, helping clinicians identify patterns, reduce waste, and improve labor efficiency [5]. Security and Efficiency Enhancements - The BD Pyxis™ Pro Dispensing Solution includes enhanced security features for controlled substance management and medication safety, as well as efficient access methods like RFID badge scanning and wireless barcode scanners [6][3]. - The solution can accommodate up to 538 multi-access or 98 secure pockets without requiring additional space, thus optimizing medication room usage [6]. Company Overview - BD is recognized as one of the largest global medical technology companies, committed to advancing health through innovative technology and solutions that enhance clinical therapy and processes [4][7].

Core Insights - BD's CFO Chris DelOrefice will leave the company on December 5, 2025, to take on a new role, with Vitor Roque appointed as interim CFO [1] - The company reported a preliminary revenue of approximately $5.9 billion for Q4 2025, reflecting an 8.3% year-over-year growth [3][5] - For the full fiscal year 2025, BD's revenue reached about $21.84 billion, marking an 8.2% increase compared to the previous year [7] - The company is transitioning from the "BD 2025" strategy to a new strategic plan called "New BD," focusing on sustainable growth and profitability [9][10] Financial Performance - Q4 2025 revenue was approximately $5.9 billion, with a year-over-year growth of 8.3% (7.0% at constant currency, 3.9% organic growth) [3][5] - Full-year revenue for 2025 was about $21.84 billion, showing an 8.2% increase (7.7% at constant currency, 2.9% organic growth) [7] - Key growth drivers included Interventional business, Advanced Patient Monitoring, and Medication Delivery Solutions, while Pharmaceutical Systems Vaccines and Biosciences faced challenges due to a slowdown in academic and government research projects [7] Strategic Transition - BD is set to unveil its "New BD" strategic plan and outlook for fiscal year 2026, indicating a shift from structural adjustments to a focus on continuous growth and profit quality [9] - The company has completed multiple integrations in surgical, drug delivery, diagnostics, and biosciences sectors, emphasizing high-growth areas like interventional therapy and digital monitoring [9] - The new strategy will prioritize profitability and cash flow quality over mere revenue expansion, as stated by CEO Tom Polen [9][10]